Y-mAbs gets FDA approval for danyelza to treat neuroblastoma
Y-mAbs Therapeutics, a commercial-stage biopharmaceutical firm, has obtained the US Food and Drug Administration (FDA) approval for danyelza (naxitamab-gqgk) to treat Neuroblastoma. The US regulatory agency indicated danyelza